Milestone Scientific Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 14, 2019 and accepted by EDGAR at Nov 14, 2019, 16:03 ET.
Management's discussion and analysis
As filed, 25,551 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements. See "Risk Factors" in Form 10-K at December 31, 2018.
OVERVIEW
Our common stock was listed on the NYSE American on June 1, 2015 and trades under the symbol “MLSS”. We have developed a proprietary, computer-controlled anesthetic delivery instrument, using The Wand, a single use disposable handpiece. The instrument is marketed in dental sector under the trademark CompuDent®, and STA Single Tooth Anesthesia System and in medical sector under the trademark CompuMed. CompuDent is suitable for all dental procedures that require local anesthetic. CompuMed is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics and several other disciplines. The dental instruments are sold in the United States, US territories, Canada, and in over 60 other countries abroad. In June 2017, the FDA approved our 510(k) application for marketing clearance in the United States of our CompuFlo Epidural Computer Controlled Anesthesia System. We are in the process of introductory meetings with medical device distributors within the United States and Europe. There have been five medical instruments sold in the United States to date and limited amounts sold internationally as of the reporting date. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.
In November 2018, Milestone Scientific received a letter from NYSE American LLC (the “Exchange”) stating that the Company was not in compliance with the continued listing standards as set forth in Section(s) 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the “Company Guide”).On December 20, 2018, the Company submitted a plan of compliance (the “Plan”) to the Exchange addressing how it intends to regain compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide by May 20, 2020.
On January 24, 2019, the Company received a letter from the Exchange stating that the Company’s Plan has been accepted by the Exchange. The Company is still not in compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide and its listing on the Exchange is being continued pursuant to an extension granted by the Exchange. If the Company is not in compliance with the continued listing standards by May 20, 2020, or if the Company does not make progress consistent with the Plan, the Exchange will initiate de-listing procedures as appropriate. The Company may appeal a staff de-listing determination in accordance with Section 10 and Part 12 of the Company Guide.
In 2019, we remain focused on advancing efforts to achieve our three primary objectives in our medical sector, those being:
- Identify distributors in the United States for the Epidural instruments, now that FDA clearance has been received;
- Worldwide distribution of the CompuFlo Epidural Computer Controlled Anesthesia System; and
- Finalize the Cosmetic device and obtain European Regulatory Approve (CE market clearance), upon securing additional funding.
Wand STA Dental Market
Since its market introduction in early 2007, the Wand/STA Instrument and prior C-CLAD products have been used to deliver over 66 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.
Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (“Henry Schein”). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. Under this arrangement we have a semi-dedicated independent sales force visiting dentists.
To date, Henry Schein has endeavored to accomplish the goals set forth in the exclusive distribution agreement for The Wand/ STA instrument and handpieces, including training of its exclusive products sale’s specialists. Specifically, up to 25 exclusive product sales specialists have now been fully trained as experts in the features, advantages and benefits of *The Wand/*STA instrument and handpieces and all are currently in the field selling the instrument.
Henry Schein also plans to increase the number of exclusive product specialist in 2020 and to train an additional customer service representative to support dentists across North America through its exclusive product sales customer call center, as business volume increases.
On the global front, we have granted exclusive marketing and distribution rights for the Wand/STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include FM Produkty Dla Stomatologii in Poland and Unident AB in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.
Medical Market
In September 2014, Milestone Medical received CE clearance to distribute their epidural and intra-articular instruments in the European Community (EU). Milestone Medical signed a distribution agreement in March 2015 with a medical distributor in Poland for the distribution of the epidural instrument. This distribution agreement was terminated in late 2016 due to the distributor’s inadequate performance under the distribution agreement. Milestone Medical is continuing to pursue distributors for the instrument in the EU community.
During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo System. In June 2017, the FDA approved the CompuFlo System for epidural injections. Milestone Scientific is in the process of meeting with medical device distributors within the United States and foreign markets. Milestone Scientific’s immediate focus is on marketing its epidural device throughout the United States and Europe.
In December 2016, we received notification from the FDA that based upon the 510(k)-application submitted for intra- articular injections, we did not adequately document that the device met the equivalency standard required for 510(k) clearances. Following consultation with the FDA’s Office of Device Evaluation, we filed a new 510(k) application for the device in June 2018. In November 2018, the FDA provided Milestone Scientific with a list of questions on the intra-articular 510(k) application filed in June 2018. Due to the delay in responding to FDA questions Milestone Scientific will be required to file a new 510(K) application, which we intend to do in 2019, subject to available funding.
In October 2018, Milestone Medical signed a Distributor Agreement in the U.S. This agreement provides that this Distributor will purchase and hold an inventory of the CompuFlo Epidural System and disposables for sale. At this time there have been no minimum purchase established with the Distributor. This Distributor purchased five CompuFlo Epidural Systems and disposables after executing the Agreement.
In April 2019, Milestone Scientific entered an Agreement with American 3B Scientific, a leading supplier of didactic material for education, for the development and sale of a CompuFlo® Epidural Training Instrument. This instructional instrument utilizes the pressure sensing technology and will be utilized as a training instrument to improve epidural placement success. The first sale of this new medical instrument occurred in May 2019, for three instruments and three disposable kits.
We have entered into a limited number of distributor arrangements in Europe and the Middle East for our CompuFlo Epidural System. Our distribution strategy is initially aimed at having KOL's use and accept the device and initiates their own studies.
In September 2019, the Company appointed a new President, Brent Johnston. The President will also be responsible for the growth of the Medical segment (Milestone Medical Inc.). The new President will evaluate the business and marketing operations of Milestone Medical Inc. over the next few months, and make the changes required to expedite the sales of the Epidural instrument in the USA and other countries in the world.
The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by product category for the three months ending September 30, 2019 and 2018:
| Domestic-US & Canada | Three months ended September 30, 2019 | 2018 |
|---|---|---|
| Devices | $216,076 | $119,190 |
| Handpieces | 812,655 | 369,027 |
| Other | 18,449 | 21,037 |
| Total Domestic US & Canada | $1,047,180 | $509,254 |
| International ROW | ||
| Devices | $391,768 | $299,872 |
| Handpieces | 451,631 | 506,880 |
| Other | 9,242 | 6,240 |
| Total International-ROW | $852,641 | $812,992 |
| International-China | ||
| Devices | $- | $- |
| Handpieces | - | 300,000 |
| Other | - | - |
| Total International | $- | $300,000 |
| Total Product Sales | $1,899,821 | $1,622,246 |
The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by product category for the nine months ending September 30, 2019 and 2018:
| Domestic-US & Canada | Nine months ended September 30, 2019 | 2018 |
|---|---|---|
| Devices | $486,360 | $251,743 |
| Handpieces | 2,632,199 | 2,296,533 |
| Other | 67,728 | 72,265 |
| Total Domestic US & Canada | $3,186,287 | $2,620,541 |
| International ROW | ||
| Devices | $1,016,683 | $952,390 |
| Handpieces | 1,714,471 | 1,924,901 |
| Other | 56,1390 | 58,519 |
| Total International-ROW | $2,787,293 | $2,935,810 |
| International-China | ||
| Devices | $- | $- |
| Handpieces | 100,000 | 300,000 |
| Other | - | - |
| Total International | $100,000 | $300,000 |
| Total Product Sales | $6,073,580 | $5,856,351 |
27
Results of Operations
The following table sets forth the consolidated results of operations For the three months ended September 30, 2019 compared to 2018. The trends suggested by this table may not be indicative of future operating results:
| Operating results: | For three months ended September 30, 2019 | 2018 |
|---|---|---|
| Product sales, net | $1,899,821 | $1,622,246 |
| Cost of products sold | 523,672 | 1,742,451 |
| Gross profit | 1,376,149 | (120,205) |
| Operating expenses: | ||
| Selling, general and administrative expenses | 2,314,943 | 2,886,081 |
| Research and development expenses | 7,940 | 1,500 |
| Impairment to long lived assets | - | 1,539,794 |
| Loss from operations | (946,734) | (4,547,580) |
| Other income, and loss on earning net | (1,903,183) | 143,015 |
| Net loss | (2,849,917) | (4,404,565) |
| Net loss attributable to noncontrolling interests | 12,941 | 11,742 |
| Net loss attributable to Milestone Scientific Inc. | $(2,836,976) | $(4,392,823) |
The following table sets forth the consolidated results of operations For the nine months ended September 30, 2019 compared to 2018. The trends suggested by this table may not be indicative of future operating results:
| Operating results: | For nine months ended September 30, 2019 | 2018 |
|---|---|---|
| Product sales, net | $6,073,580 | $5,856,351 |
| Cost of products sold | 1,894,550 | 3,326,341 |
| Gross profit | 4,179,030 | 2,530,010 |
| Operating expenses: | ||
| Selling, general and administrative expenses | 6,941,964 | 8,748,485 |
| Research and development expenses | 109,815 | 215,655 |
| Impairment to long lived assets | - | 1,539,794 |
| Loss from operations | (2,872,749) | (7,973,924) |
| Other income, and loss on earning net | (1,823,606) | 243,987 |
| Net loss | (4,696,355) | (7,729,937) |
| Net loss attributable to noncontrolling interests | 35,343 | 118,424 |
| Net loss attributable to Milestone Scientific Inc. | $(4,661,012) | $(7,611,513) |
| Cash flow: | September 30, 2019 | September 30, 2018 |
|---|---|---|
| Net cash used in operating activities | $(1,275,686) | $(1,957,602) |
| Net cash used in investing activities | (9,916) | (14,525) |
| Net cash provided by financing activities | 2,253,422 | (250,000) |
28
For the three months ended September 30, 2019 compared to three months ended September 30, 2018
Net sales for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $1,884,321 | $1,622,248 | $262,073 | 16% |
| Medical | 15,500 | - | 15,500 | 0% |
| Total sales, net | $1,899,821 | $1,622,248 | $277,573 | 17% |
Consolidated revenue for the three months ended September 30, 2019 and 2018, were approximately $1.9 million and $1.6 million, respectively. Dental revenue increased by approximately $262,000 during the three months ended September 2019 compared to 2018. Domestic revenue increase of $770,000 was primarily related to re-stocking order for handpieces and devices from Henry Schein that was received in 3rd quarter 2019. International dental revenue decreased by approximately $192,000 for the three months ended September 2019 compared to 2018. China revenue decreased for three months ended September 30, 2019 by approximately $300,000 compared to 2018.
Gross Profit for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $1,372,758 | $(120,205) | $1,492,963 | -1242% |
| Medical | 3,391 | - | 3,391 | 100% |
| Total gross profit | $1,376,149 | $(120,205) | $1,496,354 | -1245% |
Consolidated gross profit for the three months ended September 30, 2018 included a reserve of approximately $273,000 for certain dental handpieces. A claim has been made for reimbursement of this purchase to the broker and manufacture that provided the handpieces to the Company. This claim was settled in 2019, and the Company recorded a credit to cost of product sold of $151,000 towards this claim. For the three months ended September 30, 2018, the Company recorded an allowance for handpieces and devices sold to Milestone China of approximately $790,000. Consolidated gross margin for the three months ended September 30, 2019 and 2018, was approximately 72% and -7%, respectively.
Selling, general and administrative expenses for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $728,108 | $772,943 | $(44,835) | -6% |
| Medical | 550,294 | 454,306 | 95,988 | 21% |
| Corporate | 1,036,541 | 1,658,832 | (622,291) | -38% |
| Total selling, general and administrative expenses | $2,314,943 | $2,886,081 | $(571,138) | -20% |
Consolidated selling, general and administrative expenses for the three months ended September 30, 2019 and 2018, were approximately $2.3 million and $2.9 million, respectively. The decrease of approximately $571,00 is related to a decrease compensation, marketing, deprecation and professional fees of approximately $600,000 offset by an increase in travel, expense, and employee related expenses of approximately $29,000 for the three months ending September 30, 2019.
Research and Development for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $- | $- | $- | 0% |
| Medical | 7,940 | 1,500 | 6,440 | 429% |
| Corporate | - | - | - | 0% |
| Total research and development | $7,940 | $1,500 | $6,440 | 429% |
Consolidated research and development expenses for the three months ended September 30, 2019 and 2018, were approximately $8,000 and $2,000, respectively.
Profit (Loss) from Operations for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $644,650 | $(893,148) | $1,537,798 | -172% |
| Medical | (554,843) | (454,306) | (100,537) | 22% |
| Corporate | (1,036,541) | (3,200,126) | 2,163,585 | -68% |
| Total loss from operations | $(946,734) | $(4,547,580) | $3,600,846 | -79% |
The loss from operations was approximately $1.0 million and $4.5 million for the three months ending September 30, 2019 and 2018, respectively, an decrease of approximately $3.6 million. As noted above, third quarter sales in 2018 did not include the quarterly re-stocking order for handpieces and devices from Henry Schein of approximately $773,000. Additionally, during the third quarter in 2018, Milestone Scientific charged approximately $1.5 million to the Corporate segment for an impairment of long-lived assets (Apad patents). The Company also record an reserve for slow moving inventory of approximately $289,000 and a reserve of approximately $273,000 for certain dental handpieces during third quarter 2018. The dental segment of the business continues to control expenses and provided a profit for the period. Costs in the medical segment are increasing as personnel are hired in the U.S. to focus on our domestic Epidural device business.
For the nine months ended September 30, 2019 compared to nine months ended September 30, 2018
Net sales for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $6,042,580 | $5,780,251 | $262,329 | 5% |
| Medical | 31,000 | 76,100 | (45,100) | -59% |
| Total sales, net | $6,073,580 | $5,856,351 | $217,229 | 4% |
Consolidated revenue for the nine months ended September 30, 2019 and 2018 was approximately $6.1 million, and $5.9 million, respectively. Dental revenue increased by $262,00 during the nine months ended September 2019 compared to 2018. Domestic revenue increase of $770,000 was primarily related to re-stocking order for handpieces and devices from Henry Schein that was received in 3rd quarter 2019. International dental revenue decreased by approximately $192,000 for the nine months ended September 2019 compared to 2018. China revenue decreased for nine months ended September 30, 2019 by approximately $300,000 compared to 2018.
Gross Profit for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $4,168,927 | $2,710,882 | $1,458,045 | 54% |
| Medical | 10,103 | (180,872) | 190,975 | -106% |
| Total gross profit | $4,179,030 | $2,530,010 | $1,649,020 | 65% |
Consolidated gross margin for the nine months ended September 30, 2019 and 2018, was approximately 69% and 43%, respectively. During the nine months ended September 30, 2018 a reserve of approximately $273,000 for certain dental handpieces was incurred. A claim has been made for reimbursement of this purchase to the broker and manufacture that provided the handpieces to the company. This claim was settled in 2019, and the Company record a credit to cost of product sold of $151,000 towards this claim. For the nine months ended September 30, 2018, the Company recorded an allowance for handpieces and devices sold to Milestone China of approximately $790,000.
Selling, general and administrative expenses for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $2,402,840 | $2,591,269 | $(188,429) | -7% |
| Medical | 1,611,472 | 1,762,972 | (151,500) | -9% |
| Corporate | 2,927,655 | 4,394,244 | (1,466,589) | -33% |
| Total selling, general and administrative expenses | $6,941,967 | $8,748,485 | $(1,806,518) | -21% |
30
Consolidated selling, general and administrative expenses for the nine months ended September 30, 2019 and 2018 were approximately $6.9 million and $8.7 million, respectively a decrease of $1.8 million. The decrease of approximately $1.8 million is related to a decrease compensation, depreciation and professional fees of approximately $2 million offset by an increase in travel, marketing, and quality control expenses of approximately $208,000 for the three months ending September 30, 2019.
Research and Development for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $- | $- | $- | 0% |
| Medical | 109,815 | 65,008 | 44,807 | 69% |
| Corporate | - | 150,647 | (150,647) | -100% |
| Total research and development | $109,815 | $215,655 | $(105,840) | -49% |
Research and development expenses for the nine months ended September 30, 2019 and 2018, were approximately $110,000 and $216,000, respectively. The decrease is due to management discretion and curtailment in the development of several new projects that were being worked on during 2018 which was curtailed in 2019. In 2019, Management decided make modification to some Epidural instruments for the development of an Epidural trainer instruments, CompuFlo® Epidural Trainer (CompuFlo Trainer), an instructional instrument that uses pressure sensing technology to improve epidural placement success. The CompuFlo Epidural Trainer is for training purposes only and not intended for clinical use.
Profit (Loss) from Operations for 2019 and 2018 were as follows:
| 2019 | 2018 | Increase Decrease% | ||
|---|---|---|---|---|
| Dental | $1,766,087 | $119,613 | $1,646,474 | 1377% |
| Medical | (1,711,184) | (2,008,852) | 297,668 | -15% |
| Corporate | (2,927,655) | (6,084,685) | 3,157,030 | -52% |
| Total loss from operations | $(2,872,752) | $(7,973,924) | $5,101,172 | -64% |
The loss from operations was approximately $2.9 million and $7.9 million for the nine months ended September 30, 2019 and 2018 respectively an decrease of $5.1 million. As noted above, third quarter sales in 2018 did not include the quarterly re-stocking order for handpieces and devices from Henry Schein of approximately $773,000. Additionally, during the third quarter in 2018, Milestone Scientific charged approximately $1.5 million to the Corporate segment for an impairment of long-lived assets (Apad patents). The company also record an reserve for slow moving inventory of approximately $289,000 and a reserve of approximately $273,000 for certain dental handpieces during third quarter 2018. The dental segment of the business continues to control expenses and provided a profit for the period. Costs in the medical segment are increasing as personnel are hired in the U.S. to focus on our domestic Epidural device business.
Liquidity and Capital Resources
At September 30, 2019, Milestone Scientific had cash and cash equivalents of approximately $1.7 million and negative working capital of approximately $1.9 million versus working capital of $1 million at December 31, 2018. For the nine months ended September 30, 2019, we had negative cash flows from operating activities of approximately $1.3 million. Based on current and expected cash to be used in operating activities substantial doubt exists about the Company’s ability to continue as a going concern for at least the next twelve months from the filing date of this quarterly report.
Management believes that the current cash flow and support from the dental business will not be able to mitigate the expected selling expenditures for commercialization of the Epidural medical device, as well as other operating expenditures and new product development programs, over the next twelve months from the filing date of this quarterly report. Without additional funding a delay, scale back or elimination of some or all of the Company’s medical commercial strategy or development programs could be required, all of which could have a material adverse impact on the Company.
Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in February 2019 (a capital raise in a public and private offering) provided Milestone Scientific with working capital to continue marketing of the CompuFlo Epidural instrument and to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, and a reduction in operating expenses.
Now that the CompuFlo Epidural System has obtained FDA clearance in the United States (June 2017), the development costs were reduced in 2019 but the selling costs are expected to continue to increase. The FDA clearance has provided the Company with the opportunity to establish distribution in the USA. At the same time, the Company is looking to establish additional financing to support the Epidural device commercialization process. The intra-articular device is anticipated to restart the 510K application process later this year, if funding is available.
Management is actively pursuing financing or other strategic plans but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all.
Market risk
As filed, 162 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.
Controls and procedures
As filed, 1,316 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of September 30, 2019 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $1.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $6.1m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $523.7k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $1.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-07-01 to 2019-09-30 | $1.4m | us-gaap:GrossProfit |
| Gross profit | 9 months2019-01-01 to 2019-09-30 | $4.2m | us-gaap:GrossProfit |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $7.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $109.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $2.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $6.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$946.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $1.3k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $19.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$4.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-07-01 to 2019-09-30 | 47,721,732 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-30 | 43,311,984 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $9.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $5.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $6.2m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $7.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $7.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$1.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-022921. Last ingested by Listed: Nov 14, 2026, 11:14 ET. Listed shows no prices and gives no investment advice.